Basic and clinical studies on tazobactam/piperacillin in the surgical field

Jiro Yura; Nagao Shinagawa; Shu Ishikawa; Akira Mizuno; Keiji Mashita; Hiroshi Ishihara; Masazumi Hisada; Tomokatsu Fukuhara; Yoshimasa Tachi; Nobuatsu Tsuruga; Akitoshi Ito; Keiichi Hori; Hideya Okada; Takashi Miyake; Tatsuya Suzuki; Akihiko Iwai; Hiroshi Mizuno; Tetsushi Hayakawa; Yuji Okada; Shouji Kimura; Ichiya Suzuki; Akishige Nakamura; Katsuhiko Tanabe; Yota Yamagishi

doi:10.11250/chemotherapy1953.42.Supplement2_581

Basic and clinical studies on tazobactam/piperacillin in the surgical field

Jiro Yura, Nagao Shinagawa, Shu Ishikawa, Akira Mizuno, Keiji Mashita, Hiroshi Ishihara, Masazumi Hisada, Tomokatsu Fukuhara, Yoshimasa Tachi, Nobuatsu Tsuruga, Akitoshi Ito, Keiichi Hori, Hideya Okada, Takashi Miyake, Tatsuya Suzuki, Akihiko Iwai, Hiroshi Mizuno, Tetsushi Hayakawa, Yuji Okada, Shouji KimuraIchiya Suzuki, Akishige Nakamura, Katsuhiko Tanabe, Yota Yamagishi

Research output: Contribution to journal › Article › peer-review

Abstract

We performed basic and clinical studies on tazobactam/piperacillin (TAZ/PIPC), an injectable antibiotic which is a combination of piperacillin (PIPC) and tazobactam (TAZ), a newly developed β-lactamase inhibitor, in the field of surgery. The following results were obtained. 1) Delivery into bile: Concentrations of PIPC, TAZ and desethyl-piperacillin (DEt-PIPC) in bile were measured in a postoperative patient with gall stone disease after intravenous drip infusion of TAZ/PIPC at 2.5 g. The peak levels in bile were 256 μg/ml, 9.98 μg/ml and 1340 μg/ml, respectively. 2) Clinical evaluation: 24 patients with surgical infections were treated with TAZ/PIPC. Clinical efficacy was excellent in 10 cases, good in 10, fair in 2 and poor in 2, the overall efficacy rate being 83.3%. Bacteriological response was observed as eradicated in 12 cases, partially eradicated in 1, replaced in 1 and unchanged in 4, resulting in a 72.2% eradication rate. No adverse reactions were observed, and abnormal changes in laboratory findings appeared in three patients.

Original language	English
Pages (from-to)	581-589
Number of pages	9
Journal	CHEMOTHERAPY
Volume	42
DOIs	https://doi.org/10.11250/chemotherapy1953.42.Supplement2_581
Publication status	Published - 1994
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.42.Supplement2_581

Cite this

Yura, J., Shinagawa, N., Ishikawa, S., Mizuno, A., Mashita, K., Ishihara, H., Hisada, M., Fukuhara, T., Tachi, Y., Tsuruga, N., Ito, A., Hori, K., Okada, H., Miyake, T., Suzuki, T., Iwai, A., Mizuno, H., Hayakawa, T., Okada, Y., ... Yamagishi, Y. (1994). Basic and clinical studies on tazobactam/piperacillin in the surgical field. CHEMOTHERAPY, 42, 581-589. https://doi.org/10.11250/chemotherapy1953.42.Supplement2_581

@article{3d397817809e45ccb099303e5b9c98f2,

title = "Basic and clinical studies on tazobactam/piperacillin in the surgical field",

abstract = "We performed basic and clinical studies on tazobactam/piperacillin (TAZ/PIPC), an injectable antibiotic which is a combination of piperacillin (PIPC) and tazobactam (TAZ), a newly developed β-lactamase inhibitor, in the field of surgery. The following results were obtained. 1) Delivery into bile: Concentrations of PIPC, TAZ and desethyl-piperacillin (DEt-PIPC) in bile were measured in a postoperative patient with gall stone disease after intravenous drip infusion of TAZ/PIPC at 2.5 g. The peak levels in bile were 256 μg/ml, 9.98 μg/ml and 1340 μg/ml, respectively. 2) Clinical evaluation: 24 patients with surgical infections were treated with TAZ/PIPC. Clinical efficacy was excellent in 10 cases, good in 10, fair in 2 and poor in 2, the overall efficacy rate being 83.3%. Bacteriological response was observed as eradicated in 12 cases, partially eradicated in 1, replaced in 1 and unchanged in 4, resulting in a 72.2% eradication rate. No adverse reactions were observed, and abnormal changes in laboratory findings appeared in three patients.",

author = "Jiro Yura and Nagao Shinagawa and Shu Ishikawa and Akira Mizuno and Keiji Mashita and Hiroshi Ishihara and Masazumi Hisada and Tomokatsu Fukuhara and Yoshimasa Tachi and Nobuatsu Tsuruga and Akitoshi Ito and Keiichi Hori and Hideya Okada and Takashi Miyake and Tatsuya Suzuki and Akihiko Iwai and Hiroshi Mizuno and Tetsushi Hayakawa and Yuji Okada and Shouji Kimura and Ichiya Suzuki and Akishige Nakamura and Katsuhiko Tanabe and Yota Yamagishi",

year = "1994",

doi = "10.11250/chemotherapy1953.42.Supplement2_581",

language = "English",

volume = "42",

pages = "581--589",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

Yura, J, Shinagawa, N, Ishikawa, S, Mizuno, A, Mashita, K, Ishihara, H, Hisada, M, Fukuhara, T, Tachi, Y, Tsuruga, N, Ito, A, Hori, K, Okada, H, Miyake, T, Suzuki, T, Iwai, A, Mizuno, H, Hayakawa, T, Okada, Y, Kimura, S, Suzuki, I, Nakamura, A, Tanabe, K & Yamagishi, Y 1994, 'Basic and clinical studies on tazobactam/piperacillin in the surgical field', CHEMOTHERAPY, vol. 42, pp. 581-589. https://doi.org/10.11250/chemotherapy1953.42.Supplement2_581

TY - JOUR

T1 - Basic and clinical studies on tazobactam/piperacillin in the surgical field

AU - Yura, Jiro

AU - Shinagawa, Nagao

AU - Ishikawa, Shu

AU - Mizuno, Akira

AU - Mashita, Keiji

AU - Ishihara, Hiroshi

AU - Hisada, Masazumi

AU - Fukuhara, Tomokatsu

AU - Tachi, Yoshimasa

AU - Tsuruga, Nobuatsu

AU - Ito, Akitoshi

AU - Hori, Keiichi

AU - Okada, Hideya

AU - Miyake, Takashi

AU - Suzuki, Tatsuya

AU - Iwai, Akihiko

AU - Mizuno, Hiroshi

AU - Hayakawa, Tetsushi

AU - Okada, Yuji

AU - Kimura, Shouji

AU - Suzuki, Ichiya

AU - Nakamura, Akishige

AU - Tanabe, Katsuhiko

AU - Yamagishi, Yota

PY - 1994

Y1 - 1994

N2 - We performed basic and clinical studies on tazobactam/piperacillin (TAZ/PIPC), an injectable antibiotic which is a combination of piperacillin (PIPC) and tazobactam (TAZ), a newly developed β-lactamase inhibitor, in the field of surgery. The following results were obtained. 1) Delivery into bile: Concentrations of PIPC, TAZ and desethyl-piperacillin (DEt-PIPC) in bile were measured in a postoperative patient with gall stone disease after intravenous drip infusion of TAZ/PIPC at 2.5 g. The peak levels in bile were 256 μg/ml, 9.98 μg/ml and 1340 μg/ml, respectively. 2) Clinical evaluation: 24 patients with surgical infections were treated with TAZ/PIPC. Clinical efficacy was excellent in 10 cases, good in 10, fair in 2 and poor in 2, the overall efficacy rate being 83.3%. Bacteriological response was observed as eradicated in 12 cases, partially eradicated in 1, replaced in 1 and unchanged in 4, resulting in a 72.2% eradication rate. No adverse reactions were observed, and abnormal changes in laboratory findings appeared in three patients.

AB - We performed basic and clinical studies on tazobactam/piperacillin (TAZ/PIPC), an injectable antibiotic which is a combination of piperacillin (PIPC) and tazobactam (TAZ), a newly developed β-lactamase inhibitor, in the field of surgery. The following results were obtained. 1) Delivery into bile: Concentrations of PIPC, TAZ and desethyl-piperacillin (DEt-PIPC) in bile were measured in a postoperative patient with gall stone disease after intravenous drip infusion of TAZ/PIPC at 2.5 g. The peak levels in bile were 256 μg/ml, 9.98 μg/ml and 1340 μg/ml, respectively. 2) Clinical evaluation: 24 patients with surgical infections were treated with TAZ/PIPC. Clinical efficacy was excellent in 10 cases, good in 10, fair in 2 and poor in 2, the overall efficacy rate being 83.3%. Bacteriological response was observed as eradicated in 12 cases, partially eradicated in 1, replaced in 1 and unchanged in 4, resulting in a 72.2% eradication rate. No adverse reactions were observed, and abnormal changes in laboratory findings appeared in three patients.

UR - http://www.scopus.com/inward/record.url?scp=0028076194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028076194&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.42.Supplement2_581

DO - 10.11250/chemotherapy1953.42.Supplement2_581

M3 - Article

AN - SCOPUS:0028076194

SN - 0009-3165

VL - 42

SP - 581

EP - 589

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

ER -

Basic and clinical studies on tazobactam/piperacillin in the surgical field

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this